The University of Bristol spinout is working on adapting cell therapies to solid tumours.
Adam Perriman, professor of bioengineering at University of Bristol, is every tech transfer professional’s dream faculty member. He gained his PhD from Australian National University in 2007 – not long before the global financial crisis threw the world’s economies into turmoil – and immediately began pondering the benefits of spinouts, which were still a rarity…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
